Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA-S
NCT05037851Phase 2Completed
- Sponsor
- Pulmocide
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in pulmonary aspergillosis comparing Opelconazole with Standard of Care (SoC) (2 arms). Primary endpoint: Proportion of Participants Who Completed 12 Weeks of Therapy. Started Nov 2021; status: completed.
02
Drugs
opelconazole
03
Conditions
pulmonary aspergillosis
Beyond the preview
Go deeper on NCT05037851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037851.